Related references
Note: Only part of the references are listed.Downregulation of Leukocyte Migration After Treatment With CCR5 Antagonist Maraviroc
Raffaella Rossi et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
When and how to use maraviroc in HIV-infected patients
Vincent Soriano et al.
AIDS (2009)
CCR5 antagonism in HIV infection: ways, effects, and side effects
Pierre Corbeau et al.
AIDS (2009)
Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy
Benoit Marin et al.
AIDS (2009)
HIV interactions with monocytes and dendritic cells: viral latency and reservoirs
Christopher M. Coleman et al.
RETROVIROLOGY (2009)
Myeloid cells in atherosclerosis: initiators and decision shapers
Oliver Soehnlein et al.
SEMINARS IN IMMUNOPATHOLOGY (2009)
The biology of CCR5 and CXCR4
Ghalib Alkhatib
CURRENT OPINION IN HIV AND AIDS (2009)
Safety concerns about CCR5 as an antiviral target
Amalio Telenti
CURRENT OPINION IN HIV AND AIDS (2009)
Increased carotid intima media thickness is associated with depletion of circulating myeloid dendritic cells in HIV-infected patients on suppressive antiretroviral treatment
Miriam Lichtner et al.
ATHEROSCLEROSIS (2008)
Maraviroc: The first of a new class of antiretroviral agents
Rodger D. MacArthur et al.
CLINICAL INFECTIOUS DISEASES (2008)
Maraviroc: A CCR5-receptor antagonist for the treatment of HIV-1 infection
Sharon S. Lieberman-Blum et al.
CLINICAL THERAPEUTICS (2008)
Plasmacytoid Dendritic Cells Count in Antiretroviral-Treated Patients is Predictive of HIV Load Control Independent of CD4+ T-Cell Count
Claudio Mastroianni et al.
CURRENT HIV RESEARCH (2008)
Roles of MCP-1 in development of HIV-dementia
Navneet Kaur Dhillon et al.
FRONTIERS IN BIOSCIENCE (2008)
Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile Virus infection: A meta-analysis of 4 cohorts in the US epidemic
Jean K. Lim et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
HIV turns plasmacytoid dendritic cells (pDC) into TRAIL-expressing killer pDC and down-regulates HIV coreceptors by Toll-like receptor 7-induced IFN-α
Andrew W. Hardy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Increased expression of CCR5 in experimental autoimmune myocarditis and reduced severity induced by anti-CCR5 monoclonal antibody
Xuelian Gong et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2007)
Biology of CCR5 and its role in HIV infection and treatment
Michael M. Lederman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Evidence for negative binding cooperativity within CCR5-CCR2b heterodimers
L El-Asmar et al.
MOLECULAR PHARMACOLOGY (2005)
HIV type 1-infected dendritic cells induce apoptotic death in infected and uninfected primary CD4+ T lymphocytes
M Lichtner et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2004)
The role of chemokines in linking innate and adaptive immunity
AD Luster
CURRENT OPINION IN IMMUNOLOGY (2002)
Reduced blood CD123+ (lymphoid) and CD11c+ (myeloid) dendritic cell numbers in primary HIV-1 infection
J Pacanowski et al.
BLOOD (2001)
Comparative loss and maturation of peripheral blood dendritic cell subpopulations in African and non-African HIV-1-infected patients
GJ Jones et al.
AIDS (2001)
Desensitization of chemokine receptor CCR5 in dendritic cells at the early stage of differentiation by activation of formyl peptide receptors
YY Le et al.
CLINICAL IMMUNOLOGY (2001)
Differential regulation of formyl peptide receptor-like 1 expression during the differentiation of monocytes to dendritic cells and macrophages
D Yang et al.
JOURNAL OF IMMUNOLOGY (2001)
Advances in immunology: Innate immunity.
R Medzhitov et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
